ArticleAmerican journal of hypertension2026
Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation.
Article in American journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Aldosterone excess, blood pressure control, and kidney outcomes in chronic kidney disease: findings from the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.Circulation research · 2026Review
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Unmasking Hormonal Mechanisms of Hypertension in Obesity.JACC. Basic to translational science · 2026Article
- Unmasking Hormonal Mechanisms of Hypertension in Obesity.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundExcess aldosterone of >15 ng/dL, in the presence of low renin, is linked to hypertension (HTN) and chronic kidney disease (CKD). This study investigated the association of aldosterone dysregulation at lower plasma aldosterone levels (≥5 ng/dL) with the risk of uncontrolled HTN and CKD prevalence.
methodsPatient plasma aldosterone measurements obtained during 2013-2023 were identified in the TriNetX Dataworks-USA Network of electronic medical records. Eligible patients (≥18 years) had a plasma renin activity measurement of ≤1 ng/mL/h within 12 months before, and a systolic blood pressure (SBP) measurement within 12 months following, the index aldosterone measurement. The primary outcome was uncontrolled HTN (SBP ≥130 mmHg) prevalence. The secondary outcome was CKD prevalence (CKD diagnosis or eGFR measurement of <60 mL/min/1.73 m2). The adjusted odds ratio (aOR) of uncontrolled HTN during a 12-month follow-up was calculated among plasma aldosterone groups (≥5 vs <5 ng/dL, ≥10 vs <10 ng/dL, and ≥15 vs <15 ng/dL).
resultsPatients (N = 1334) had a mean age of 59 years, and 55.9% were female. Patients with plasma aldosterone of ≥5 ng/dL (N = 903) had a higher risk (aOR [95% CI]) of uncontrolled HTN (2.01 [1.38-2.92]; P < .001) versus <5 ng/dL (N = 431). Similar findings were observed for plasma aldosterone levels of ≥10 ng/dL and ≥15 ng/dL. Patients with plasma aldosterone of ≥10 ng/dL (N = 514) had a higher risk of CKD (1.49 [1.15-1.92]; P < .001) versus <10 ng/dL (N = 820). Similar findings were observed for plasma aldosterone levels of ≥15 ng/dL.
conclusionsClinically relevant aldosterone dysregulation, in the presence of low renin, occurs at lower aldosterone levels than previously thought, and remains significantly associated with uncontrolled HTN and CKD prevalence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.